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A B S T R A C T
Background: The global push for the use of hydroxychloroquine (HCQ) and chloroquine (CQ) against
COVID-19 has resulted in an ongoing discussion about the effectivity and toxicity of these drugs. Recent
studies report no effect of (H)CQ on 28-day mortality. We investigated the effect of HCQ and CQ in
hospitalized patients on the non-ICU COVID-ward.
Methods: A nationwide, observational cohort study was performed in The Netherlands. Hospitals were
given the opportunity to decide independently on the use of three different COVID-19 treatment
strategies: HCQ, CQ, or no treatment. We compared the outcomes between these groups. The primary
outcomes were 1) death on the COVID-19 ward, and 2) transfer to the intensive care unit (ICU).
Results: The analysis included 1064 patients from 14 hospitals: 566 patients received treatment with
either HCQ (n = 189) or CQ (n = 377), and 498 patients received no treatment. In a multivariate propensity-
matched weighted competing regression analysis, there was no significant effect of (H)CQ on mortality
on the COVID ward. However, HCQ was associated with a significantly decreased risk of transfer to the ICU
(hazard ratio (HR) = 0.47, 95% CI = 0.27–0.82, p = 0.008) when compared with controls. This effect was not
found in the CQ group (HR = 0.80, 95% CI = 0.55–1.15, p = 0.207).
Conclusion: The results of this observational study demonstrate a lack of effect of (H)CQ on non-ICU
mortality. However, we show that the use of HCQ — but not CQ — is associated with a 53% reduction in risk
of transfer of COVID-19 patients from the regular ward to the ICU. Recent prospective studies have
reported on 28-day, all-cause mortality only; therefore, additional prospective data on the early effects of
HCQ in preventing transfer to the ICU are still needed.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Abbreviations: HCQ, hydroxychloroquine; CQ, chloroquine; AZM, azithromycin; ICU, intensive care unit; ED, emergency department.
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After the emergence of SARS-CoV-2 in December 2019, the new
oronavirus spread around the world, resulting in a pandemic.
nfortunately, there is still no proven effective drug or vaccine
vailable against COVID-19, and hospitalized patients with COVID-
9 are at high risk for admission to the ICU (10–20%), with 3–10% of
atients requiring intubation, and 2–5% of patients dying (Guan
t al., 2020).
Among the drug candidates for treating COVID-19 are
ydroxychloroquine (HCQ) and chloroquine (CQ) (Sanders et al.,
020). Insights into the underlying mechanisms of action of HCQ
nd CQ are still emerging. Both drugs have a large volume of
istribution (Zhou et al., 2020; Schrezenmeier and Dörner, 2020).
heir molecular structures are comparable, except that HCQ has an
xtra hydroxyl group. Both interfere with lysosomal activity and
ecrease membrane stability, reduce signaling pathways for Toll-
ike-receptors 7 and 9, and impact on transcriptional activity,
nhibiting cytokine production (Schrezenmeier and Dörner, 2020).
There are only a few differences between the drugs, of which
he most important is drug clearance (Schrezenmeier and Dörner,
020).
Some observational studies on the efficacy of (H)CQ report
linical benefits and antiviral effects (Gao et al., 2020; Gautret et al.,
020; Arshad et al., 2020; Cortegiani et al., 2020), while others do
ot (Geleris et al., 2020; Mahevas et al., 2020). A few small,
ontrolled trials have been inconclusive (Tang et al., 2020; Chen
t al., 2020). The Recovery study included 176 UK hospitals,
omprising 1395 patients receiving high doses of HCQ (9200 mg
umulative dose), and reported no beneficial effects on all-cause
ortality at 28 days (26.8% of treated patients versus 25% of
ontrols) (Horby, 2020). The risk of admission to the ICU could not
e calculated, since 17–60% of patients were already on (non-
nvasive) ventilation at randomization. A recent systematic review
nd meta-analysis, including 11 932 patients on HCQ, found that its
se was not associated with reduced mortality (pooled relative risk
f RCTs for HCQ use of 1.09) (Fiolet et al., 2020).
Results of other prospective trials are not expected, since the
uropean Discovery and the WHO Solidarity trials have discon-
inued their HCQ treatment arms because of lack of effect on
ortality. Meanwhile, the US FDA and the Infectious Diseases
ociety of America (IDSA) advise against the use of (H)CQ outside
he context of a clinical trial (Swank and McCarten, 2020;
nfectious Diseases Society of America Guidelines, 2020).
Based on the available evidence present at the start of the
utbreak, a Dutch treatment guideline was developed (RIVM,
020). Off-label use of both HCQ and CQ was offered as a treatment
ption; however, the guidelines did not endorse either treatment
n particular. Consequently, hospitals decided independently on a
reatment protocol with either HCQ or CQ, or to give no treatment.
his policy created a unique situation for comparing the efficacy of
CQ and CQ with no treatment in hospitalized non-ICU patients,
ith a reduction of potential bias by indication.
ethods
tudy design
The study was designed as an observational, multicenter, cohort
tudy of hospitalized COVID-19 patients. Before the first patients
the clinical endpoints: (1) discharge for cured infection to home or
rehabilitation center; (2) transfer from the COVID ward to the
intensive care unit (ICU); or (3) death, either during their hospital
stay on the ward (non-ICU) or following transfer to a hospice
facility. Secondary outcomes were the effects of the use of
azithromycin (AZM) and angiotensin-receptor blockers (ARB) on
outcome.
Participating hospitals
All hospitals in The Netherlands were considered eligible to
participate in the study, including academic hospitals as well as
non-teaching hospitals. These hospitals were asked to participate
early in the outbreak. All participating hospitals shared their data
with the coordinating hospital (Isala, Zwolle), where the statistical
analysis was performed. Data-sharing agreements were signed,
and the Medical Ethics Review Committee (METC) of Isala
approved a waiver for informed consent.
Patients
Inclusion and exclusion criteria were designed to select a study
sample of hospitalized patients with moderate to severe COVID-19.
New confirmed COVID-19 cases were included if they were aged >
18 years and if they were admitted to the emergency department
(ED) and subsequently hospitalized on the non-ICU hospital
COVID-19 ward. Exclusion criteria were age < 18 years, admission
to the ICU, or death within 24 h after presentation at the ED.
Patients transferred between Dutch hospitals, for example due to
capacity issues, were also excluded. Confirmed COVID-19 infection
was defined as either positive SARS-CoV-2 real-time reverse
transcriptase polymerase chain reaction (PCR) on swab material,
sputum, or bronchoalveolar lavage samples (Corman et al., 2020),
or typical findings on chest computed tomography (CT). Typical CT
findings were defined as CO-RAD 4–5, using the CO-RAD
classification system (COVID-19 Reporting and Data System,
developed by the Dutch Radiology Society to describe levels of
suspicion for COVID-19 infection) (Prokop et al., 2020). Routine
blood tests were carried out for hematological and biochemical
analysis, according to standard hospital laboratory techniques.
Since the use of (H)CQ for COVID-19 was off-label, patients were
started on (H)CQ only after giving informed consent. HCQ was
dosed: on day 1 400 mg and 400 mg after 12 h, 200 mg bid on day
2–5. CQ was dosed: on day 1 600 mg and 300 mg after 12 h, 300 mg
bid on day 2–5.
Data collection
Data were extracted from Electronic Health Records (EHR) in all
participating hospitals by medical students and/or infectious
disease (ID) physicians. Data were collected on site using a
standardized data-collection form on a secured website of the
coordinating hospital. Patient data were immediately anonymized
and encoded upon entry into the online research manager
program. Collected data included patient characteristics, such as
comorbidities, registered ICU-restrictive policy by treating physi-
cian, routine laboratory results, SARS-Cov2-PCR and chest CT-scan
results, medical treatment before admission, and antibiotic
treatment during hospitalization.ere admitted, Dutch hospitals independently implemented a
reatment protocol with or without (H)CQ. As a consequence,
utch patients were geographically allocated to their local hospital
ith or without the intention to treat with (H)CQ. Eligible patients
ere included retrospectively over the period from February 28 to
pril 1, 2020. Patients were followed up until they reached one of28Statistical analysis
Differences between HCQ and CQ users (cases) and non-users
(controls) were compared using χ2 statistics or the Fisher exact test
for categorical variables, and the independent t-test or Mann-
Whitney U test for continuous variables. The data were analyzed4
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commenced from the date of hospital admission and ended on the
dates of death or ICU admission, and patients were censored at the
time they were discharged from hospital. Hazard ratios were
calculated for (H)CQ use in relation to the primary endpoints of
death and ICU admission, or a combination of these endpoints
denoted as a composite adverse endpoint. Death and ICU
admission are competing risk events; therefore, competing risk
regression analysis was conducted for these two endpoints
according to the method developed by Fine and Gray (1999).
Instead of KM survival curves, survival data were summarized
using the cumulative incidence function (CIF) or cumulative risks
of an event, which indicate the probability of the event at a given
time. The proportional hazards assumption was confirmed by
Schoenfeld’s global test and inspection of log (log [survival])
curves. Propensity score (PS) matching was used for making causal
inferences for the treatment on the clinical outcome. A set of pre-
test covariates that were associated with the treatment was
selected and PS scores were estimated using logistic regression,
with treatment as the outcome measure. Separate PS-matched Cox
regression models with and without adjustment for potential
confounders were used including the covariate-adjusted, strati-
fied, matched and weighted analyses. Only the results of the overall
and inverse-probability-of-treatment-weighted (IPTW) Cox re-
gression analysis are shown, because in time-to-event analyses,
IPTW is the best method to minimize bias (Austin, 2013). Analyses
were adjusted for gender, age, comorbidity CVA, comorbidity
diabetes, comorbidity asthma/COPD, use of broad-spectrum anti-
biotics, therapeutic anticoagulation, prophylactic anticoagulation,
first day at ED, and ICU restriction. The combined endpoint risk Cox
regression analyses were stratified by ICU restriction, because of
the distinctive patient characteristics in this group. For PS
estimation and matching the PS matching R package in SPSS
and the PSMATCH2 package in Stata were used. All tests were two-
sided and p < 0.05 was considered statistically significant.
Statistical analyses were performed using SPSS version 24.0 and
the STATA version 14 statistical package (Stata Corporation, College
Station, TX).
Results
Inclusion and baseline characteristics
Between February 28 and April 1, 2020, 1130 patients admitted
to the 14 participating hospitals in The Netherlands met the
inclusion criteria; 1106 patients were eligible for inclusion. After
propensity score matching the analytic cohort consisted of 1064
patients, comprising 566 (53.2%) treated patients, both with HCQ
(N = 189; 17.8%) and CQ (N = 377; 35.4%), and 498 (46.8%) untreated
controls (see Figure 1).
Table 1 shows the characteristics of the study population. The
distribution of patients over the three hospital groups was as
follows: 270 patients (25.4%) were admitted to an HCQ hospital,
532 (50%) to a CQ hospital, and 262 (24.6%) to a hospital with a
protocol of no additional treatment. In both HCQ and CQ hospitals
at least 70% of patients received treatment. Median time from
admission to receipt of treatment was short: 1 day in both groups
(HCQ 1.00, SD 1.5 days; CQ 1.00, SD 1.19 days). Most patients were
male (60%) and body mass index (BMI) was 28 in all three groups.
Comorbidities were comparable, except for cardiac disease, which
saw a higher incidence in the non-treated group. Some patients
had an ICU-restrictive policy, for instance due to comorbidity or
high age: in the HCQ group 36% of patients had an ICU restriction
(68/189), in the CQ group 30.5% (115/377), and 48.5% of patients
without treatment (242/498) were not considered eligible for
admission to the ICU. During follow-up,191 patients (18%) died,147
(13.8%) were admitted to the ICU, and 726 (68.2%) were discharged
from the hospital upon recovery.
Primary outcomes
Table 2 shows the results of the unadjusted and adjusted overall
and weighted competing risk analyses for the different endpoints
by type of medication. Figure 2A and B show the corresponding
cumulative incidence functions (CIF). Multivariate analysis proves
that both CQ and HCQ use were not statistically associated with a
risk of death on the non-ICU COVID ward (for CQ, hazard ratio (HR)
= 0.99, 95% CI = 0.70–1.43; for HCQ, HR = 0.96, 95% CI = 0.63–1.45).Figure 1. Number of included COVID-19 patients.
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ecreased risk of transfer to the ICU (HR = 0.47, 95% CI = 0.27–0.82,
 = 0.008) when compared with controls. This effect was not found
n the CQ group (HR = 0.80; 95% CI = 0.55–1.15, p = 0.207). In
ddition, for the composite adverse endpoint, a significantly
ecreased risk was observed for HCQ (HR = 0.68, 95% CI = 0.49–
Secondary outcomes
Since the use of azithromycin (AZM) and angiotensin receptor
blockers (ARB) has been postulated to have an effect on COVID-19,
we additionally analyzed the effect of this treatment on outcome;
210 patients were started on AZM therapy on admission, while 854
able 1
haracteristics of the study population.
Total (N = 1064) Chloroquine centers (N = 532) Hydroxychloroquine centers (N = 270) No therapy centers (N =
262)
Variable Treated No treatment Missing p Treated No treatment Missing p All Missing
Total: N, % 377 35.4 155 14.6 189 17.8 81 7.6 262 24.6
Gender (male): N, % 244 64.7 78 50.3 0 0.002* 123 65.1 43 53.1 0 0.063* 156 59.5 0
Age: M, SD 66.4 13.5 71.8 15.3 0 0.000z 64.7 14.5 63.9 17.2 0 0.944z 68.8 14.8 0
BMI: M, SD 28.2 4.9 28.1 5.3 98 0.996z 27.5 4.1 28.5 6.2 147 0.537z 27.7 5.4 69
ICU restriction: N, % 115 30.8 86 55.5 0 0.000* 68 36 29 36 0 0.978* 127 48.5 0
Comorbidities: N, %
Hypertension 133 35.3 65 41.9 0 0.149* 62 32.8 25 30.9 0 0.755* 103 39.3 0
Heart failure 15 4 24 15.5 0 0.000* 12 6.3 11 13.6 0 0.051* 36 13.7 0
Myocardial infarction 29 7.7 16 10.3 0 0.322* 6 3.2 7 8.6 0 0.054* 27 10.3 0
Atrial fibrillation 43 11.4 41 26.5 0 0.000* 22 11.6 13 16 0 0.323* 34 13 0
CVA 31 8.2 22 14.2 0 0.037* 10 5.3 3 3.7 0 0.577* 20 7.6 0
Diabetes type 1 or 2 69 18.3 46 29.7 0 0.004* 47 24.9 17 21 0 0.492* 49 18.7 0
Asthma or COPD 80 21.2 35 22.6 0 0.729* 21 11.1 17 21 0 0.032* 54 20.6 0
OSAS 24 6.4 6 3.9 0 0.261* 9 4.8 2 2.5 0 0.382* 18 6.9 0
Chronic kidney disease (creat. > 150
mmol/L)
14 3.7 7 4.5 1 0.670* 12 6.3 5 6.2 0 0.956* 20 7.6 1
Active malignancy 29 7.7 12 7.7 0 0.984 14 7.4 6 7.4 0 1* 17 6.5 0
Muscle disease 5 1.3 1 0.6 0 0.499* 1 0.5 1 1.2 0 0.536* 6 2.3 1
History of DVT/LE 23 6.1 8 5.2 0 0.686* 11 5.8 5 6.2 0 0.91* 23 8.8 0
Immunosuppressive 23 6.1 8 5.2 0 0.674* 8 4.2 1 1.2 0 0.208* 32 12.2 0
Diagnosis based on . . . : N, %
PCR 359 95.2 145 93.5 0 0.431* 180 95.2 79 96.3 0 0.699* 252 96.2 0
CT 16 4.2 8 5.2 0 0.643* 9 4.8 2 2.5 0 0.382* 9 3.4 0
Clinical judgement 2 0.5 2 1.3 0 0.357* 0 0 0 0 0 N/A 1 0.4 0
Vitals and laboratory results at presentation: M (N), SD
Temperature 38.1 1.0 37.9 1.0 1 0.009x 38.1 1.0 38.0 1.0 1 0.476z 38.0 1.05 1
Oxygen needed: N, % 326 86.5 93 60 0 0.000* 167 88.4 56 69.1 0 0.000* 163 62.2 0
CRP 97 72.9 83.1 75.8 2 0.003z 105.3 76.9 64.1 48.5 28 0.0000z 88.3 74.9 3
Leucocytes 7.0. 3.1 6.9 3.4 6 0.313z 7.0 5.1 7.3 4.0 29 0.524z 7.0 3.0 3
Lymphocytes 1.0 1.4 1.0 1.0 20 0.901z 1.3 4.4 1.3 1.1 63 0.006z 1.1 1.0 37
Platelets 207.9 83.5 204.9 81.2 11 0.443z 205.6 95.68 177.6 107.4 67 0.357z 203.3 86.2 6
Creatinine 93.1 44.7 106 68.1 3 0.090z 92.8 73.5 103.0 112.6 29 0.096z 107.9 107.6 4
LDH at presentation 356.2 142.3 312.2 118.5 40 0.000z 346.7 148.1 340.1 140.1 54 0.692z 347.2 143.6 22
Pre-hospital medication: N, %
ACE inhibitors 55 14.6 34 22.1 2 0.037* 30 16.0 15 18.8 0 0.588* 52 20.1 3
Angiotensine-2 receptor
antagonists
48 12.8 24 15.6 2 0.390* 25 13.4 9 11.3 4 0.624* 27 10.5 4
Therapeutic anticoag. 50 13.3 37 24 2 0.002* 29 15.8 17 21.5 7 0.26* 51 19.9 6
In-hospital medication
Broad-spectrum antibiotics: N, % 327 86.7 99 63.9 0 0.000* 185 97.9 71 87.7 0 0.0010* 196 74.8 0
Azithromycin: N, % 31 8.2 33 21.3 0 0.000* 48 25.4 45 55.6 0 0.0000* 53 20.2 0
Cumulative dosage AZM: M (N), SD 833.3 461.1 1241.9 560.8 3 0.001z 2020.8 1115.5 1661.1 834.5 0 0.137z 2264.4 925.4 1
Cumulative dosage CQ/HCQ: M (N),
SD
2179.5 897.6 N/A N/A 1 N/A 1823.5 636.1 N/A N/A 19 N/A N/A N/A N/A
Therapeutic anticoag.: N, % 66 17.5 51 32.9 0 0.000* 38 20.1 19 23.5 0 0.536* 56 21.4 0
Prophylactic anticoag.: N, % 318 84.4 99 63.9 0 0.000* 161 85.2 57 70.4 0 0.005* 148 56.5 0
Deep venous thrombosis: N, % 1 0.3 0 0 3 0.519* 0 0 0 0 1 N/A 2 0.8 3
Pulmonary embolism: N, % 6 2.1 1 0.8 115 0.355* 3 1.6 0 0 4 0.253* 4 1.5 3
Endpoints
Discharged for cured infection: N, % 245 65.0 107 69.0 0 0.370* 139 73.5 58 71.6 0 0.742* 177 67.6 0
ICU admission: N, % 72 19.1 10 6.5 0 0.000* 20 10.6 3 3.7 0 0.064* 42 16.4
=16.0
0
Death or hospice: N, % 60 15.9 38 24.5 0 0.020* 30 15.9 20 24.7 0 0.087* 43 16.0
=16.4
0
 = mean, SD = standard deviation, *= χ2 test, † = Fisher exact test, x = independent t-test, z = non-parametric Mann-Whitney test, HCQ = hydroxychloroquine, CQ =
hloroquine, AZM = azithromycin, BMI = body mass index, ICU = intensive care unit, CVA = cerebrovascular accident, OSAS = obstructive sleep apnea syndrome..95, p = 0.024) but not for CQ use (HR = 0.85, 95% CI = 0.66–1.10, p =
.224).28patients did not receive AZM. In the KM analysis there was no
significant difference between these two groups in reaching the
composite adverse endpoint (Plogrank = 0.071) and no significant
interaction effect was found for H(CQ) combined with AZM use (p =
0.2195).6
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antagonists (ARB, n = 70) or angiotensin-converting enzyme
inhibitors (ACEi, n = 110), and continued treatment during
admission. There was no difference in outcome for the composite
adverse endpoint for continued ACEi use (HR = 1.21; 95% CI = 0.78–
1.90, p = 0.397) nor for continued ARB use (HR = 1.21; 95% CI = 0.70–
2.10, p = 0.498), as compared with no therapy.
Discussion
This study demonstrated a new and clinically important
finding: the use of HCQ on the COVID-19 ward is associated with
a decreased risk of transfer to the ICU. After weighted competing
risk analysis, the risk of admission to the ICU was reduced by 53%.
This finding suggests that starting early treatment with HCQ
(within 1 day of admission) on the regular COVID ward might
prevent progression to critical respiratory illness. This is consistent
with the suggestion that HCQ treatment reduces the risk of disease
progression more effectively earlier in the course of the disease (
Perinel et al., 2020; Wang et al., 2020b). This holds true for many
other viral infections, such as influenza and herpes simplex, where
treatment must be initiated soon after onset of symptoms in order
to confer benefit. However, treatment with HCQ before onset of
symptoms did not prevent COVID-19, as was demonstrated in a
randomized controlled trial investigating postexposure use of HCQ
(Boulware et al., 2020).
Second, we could not demonstrate a significant effect of
treatment with HCQ or CQ on on-ward mortality. One of the
strengths of our study was that we selected a clearly defined cohort
of patients on the regular non-ICU COVID-ward, thus our results
reflected mortality before transfer to the ICU only. In recent
literature, evidence is accumulating that there is no beneficial
effect of HCQ on mortality. Mortality numbers in systematic
reviews and in prospective HCQ studies, such as the Recovery trial,
are frequently reported in terms of 28-day all-cause mortality, and
do not differentiate between on-ward mortality and mortality after
Table 2
Clinical outcome hazard ratio (HR) estimates for HCQ and CQ use among COVID19 patients under separate risk models.
N = 1012* Endpoint: death Endpoint: ICU admission Combined endpoint
Unadjusted Adjusted3 Unadjusted Adjusted4 Unadjusted Adjusted5*
Model Drug
use
HR 95% CI p-
value
HR 95% CI p-
value
HR 95% CI p-
value
HR 95% CI p-
value
HR 95% CI p-
value
HR 95% CI p-value
Overall1 None
(ref)


























































1Cox regression model without propensity score (PS) adjustment and competing regression analysis; 2competing risk regression with weighted PS adjustment (see statistical
method section for explanation of the different models); HR = hazard ratio; CI = confidence interval; CQ = chloroquine; HCQ = hydroxychloroquine; *total number of patients
in the analysis; 3,4,5adjusted for gender, age, comorbidity CVA, comorbidity diabetes, comorbidity asthma/COPD, use of broad-spectrum antibiotics, therapeutic
anticoagulation, prophylactic anticoagulation, first day in ED, ICU restriction.
The weighted Cox-regresion analyses for the combined endpoints were stratified by ICU restriction to reflect underlying potential differences in adverse incidences and risk
factor prevalences.Figure 2. Cumulative incidence functions (CIF) by type of medication. A.
Cumulative risk of death. B. Cumulative risk of transfer to ICU.
287transfer to the ICU (Horby, 2020; Fiolet et al., 2020).
In our study, there was no significant difference in outcome
between patients treated with AZM, nor in patients on ACEi or ARB
therapy. It has been suggested that ARB therapy increases
susceptibility to COVID-19, but other studies report conflicting
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n-hospital continuation of ACEi or ARB therapy.
Surprisingly, we found a differential effect of HCQ and CQ on
OVID-19, while in the literature these drugs are frequently
eported in terms of a composite outcome. There are several
ossible explanations for this differential effect. The first
xplanation is a difference in pharmacokinetics between both
rugs. There is a substantial difference in renal drug-clearance –
1% in CQ and 21% in HCQ (Schrezenmeier and Dörner, 2020).
urthermore, the distribution volumes of HCQ and CQ are
ifferent; HCQ has a volume of distribution of 5522 liters (whole
lood), as compared with 14 000–56 000 liters for CQ (Drugbank,
020a; Furst, 1996; Drugbank, 2020b). It is still a matter of debate
hether the 4-aminoquinoline drugs have anti-viral activity or
mmunomodulating properties (Gautret et al., 2020; Maisonnasse
t al., 2020). The immunomodulating effect of HCQ in has been
eported in rheumatology literature (Schrezenmeier and Dörner,
020). In clinical practice, patients with rheumatoid disease are
reated with HCQ but not CQ as anti-inflammatory therapy,
ccording to clinical guidelines (Arayssi et al., 2018). It is
onceivable that the beneficial effect of early HCQ in COVID-19
ies in the reduction of localized inflammation in the lung. This is
upported by the results of a recent observational study, which
ndicated that the use of moderate-dose systemic corticosteroids
n the general ward lowered the hazard of ICU transfer
Majmundar et al., 2020).
Another important strength of our study was the random
istribution of patients between hospitals with different treatment
rotocols. Unintentionally, three groups of patients were created,
lmost as in prospective research. We were able to investigate the
ifferences between patients on or off treatment with a reduced
isk of bias by indication.
This study had some limitations. First, all observational cohort
tudies are prone to bias by confounding. We used weighted
ropensity scores to adjust optimally for differences between
reated patients and controls. However, randomized studies are
eeded to confirm our data. Another limitation of this study was a
ack of data on the adverse effects of (H)CQ. There is ongoing global
iscussion about possible drug toxicity in COVID-19 patients and
ncreased mortality associated with HCQ treatment (Borba et al.,
020; Magagnoli et al., 2020). Since HCQ and CQ are FDA- and
MA-approved drugs, the adverse effects are well documented
Fosbøl et al., 2020). Yet these adverse effects are similar to the
ommonly reported COVID-19 symptoms (fever, fatigue, dry
ough, dyspnea, myalgia), while nausea and diarrhea are also
requently observed (Guan et al., 2020; Wang et al., 2020a). Older
atients are more likely to have abdominal complaints as
resenting symptoms of COVID-19 (Godaert et al., 2020). Because
f the difficulty in distinguishing symptoms of COVID-19 from
dverse effects of (H)CQ treatment we decided to refrain from
ollecting patient-reported symptoms retrospectively.
It is postulated that the pathophysiology of COVID-19 is
haracterized by three phases of illness (Siddiqi and Mehra,
020). In the initial viral stage phase (phases 1-stage (phases 1-2)
atients are moderately affected (phase 1), viral replication and
ocalized inflammation in the lung cause hypoxemia and
ymphopenia, and patients are admitted to the hospital cohort-
ard. This phase ward (phase 2). This is followed by systemic
yperinflammation (phase 3) and severe disease, where patients
re potentially admitted to the ICU for invasive mechanical
COVID-19 patients is associated with a decreased risk of transfer to
the ICU. Once patients are critically ill, the process of hyper-
inflammation and hypercoagulation is probably not influenced by
HCQ, and treatment with strong immunosuppressants and
anticoagulant therapy are more important for the survival of
patients with severe COVID-19.
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